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Starting with the discovery of streptomycin, the promise of natural products research
on actinomycetes has been captivating researchers and offered an array of life-
saving antibiotics. However, most of the actinomycetes have received a little attention
of researchers beyond isolation and activity screening. Noticeable gaps in genomic
information and associated biosynthetic potential of actinomycetes are mainly the
reasons for this situation, which has led to a decline in the discovery rate of
novel antibiotics. Recent insights gained from genome mining have revealed a
massive existence of previously unrecognized biosynthetic potential in actinomycetes.
Successive developments in next-generation sequencing, genome editing, analytical
separation and high-resolution spectroscopic methods have reinvigorated interest on
such actinomycetes and opened new avenues for the discovery of natural and natural-
inspired antibiotics. This article describes the new dimensions that have driven the
ongoing resurgence of research on actinomycetes with historical background since
the commencement in 1940, for the attention of worldwide researchers. Coupled with
increasing advancement in molecular and analytical tools and techniques, the discovery
of next-generation antibiotics could be possible by revisiting the untapped potential of
actinomycetes from different natural sources.
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INTRODUCTION
Actinomycetes are ubiquitous Gram-positive bacteria that constitute one of the largest bacterial
phyla with characteristic filamentous morphology and high G+C DNA. The actinomycetes have
been recognized as premier source and inspiration for a substantial fraction of antibiotics that play
an important role in human health. The most striking fact is that these filamentous bacteria have
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FIGURE 1 | Graphical summary of research and developments focused on antibiotic discovery from actinomycetes over 76 years. Hunting of antibiotics
from actinomycetes has emanated with the discovery of actinomycin in 1940 (a) and lined up with several commercially important antibiotics and their derivatives:
streptomycin (a), cephalosporins (b), Chloramphenicol (c), neomycin (d), tetracycline (e), nystatin (f), virginiamycin (g), erythromycin (h), lincomycin (i), vancomycin (j),
noviobiocin (k), rifamycin (l), kanamycin (m), nalidixic acid (n), fusidic acid (o), gentamicin (p), trimethoprim (q), fostomycin (r), ribostamycin (s), mupiriocin (t), linezolid
(u), daptomycin (v), and platensimycin (w). Classic actinomycetes research was driven by isolation and activity screening approach. Whereas, modern actinomycetes
research is driven by array of breakthroughs in genetics, genomics, metagenomics, genome mining and editing and high-resolution metabolomics, in association
with classical approach.
evolved with the wealth of biosynthetic gene clusters and thereby
show an unprecedented potential in production biologically
active natural product scaffolds. However, last two decades has
seen a move by pharmaceutical giants away from microbial
natural product discovery efforts, and such efforts continue
to flourish in research institutes with promising results. The
continued research efforts of academic research institutes,
with post-genomic technological innovations, rejuvenate natural
product research and compose a clarion call to worldwide
researchers for tuning into microbial natural products research.
THE CLASSIC ACTINOMYCETES
RESEARCH
If we look back to about 76 years of actinomycetes research
that focused on hunting bioactive metabolites of public welfare,
over 5000 compounds have been reported and contributed
to the development of 90% of commercial antibiotics being
used for either clinical or research needs. In this long
course, actinomycetes research evolved several aspects from
isolation and activity screening to modern post-genomic
secondary metabolites research (Figure 1). The first report of
streptomycin by Selman Waksman and associates in the 1940s
and subsequent development as drug encouraged pharmaceutical
companies and researchers to put their large scale efforts on
microbial natural products research (Demain and Sanchez,
2009). The efforts were largely depending on the recovery
of microorganisms from diverse environmental samples, and
screening for the desired bioactivity. The approach brought the
golden era (1950–1970) of antibiotic discovery evidenced by
the commercialization of several life-saving antibiotics including
streptomycin, vancomycin, rifamycin, and so on (Mahajan and
Balachandran, 2012). In subsequent decades, the rediscovery
of known compounds and technical challenges associated
with purification and structure elucidation of new compounds
largely declined the classic efforts (Bérdy, 2012). Despite the
evidence of a decline in microbial natural products research,
continued innovations in sampling and acquisition of potential
actinomycetes from previously unexplored sources are being
continued by several academic research groups and mitigate
risks of the rediscovery of known compounds and augmented
availability of diverse actinomycetes that are fundamental matters
to the long term actinomycetes research.
IN PROGRESS
Progress is crucial in several aspects of actinomycetes research
that includes (1) isolation and dereplication of actinomycete
isolates, (2) prediction and identification novel compounds,
(3) enhancing production titers of potential compounds, (4)
uncovering genome information and associated biosynthetic
potential, (5) collection and processing of genomic data, (6)
mining, editing and heterologous expression of cryptic gene
clusters, and (7) comprehensive metabolic profiling, under a
broad spectrum of main areas such as genetics, genomics and
metabolomics.
Establishing actinomycete resources is one of the basic
requirements for culture-dependent natural products research.
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To address this, researchers are learning how to cultivate the
unexplored actinomycete biodiversity in diverse environments
and such efforts have led to cultivation of numerous novel
actinomycetes from marine sediments (Becerril-Espinosa et al.,
2013), hydrothermal vents (Thornburg et al., 2010), solar salterns
(Jose and Jebakumar, 2013), desert soils (Mohammadipanah and
Wink, 2016), red soils (Guo et al., 2015), sponges (Sun et al.,
2015), insects (Matsui et al., 2012; Kurtböke et al., 2015), and
plants (Masand et al., 2015). On the other hand, dereplication of
isolated strains has attained a new pitch with gene specific as well
as metabolic fingerprinting approaches (Hou et al., 2012; Forner
et al., 2013). Collectively, the united success in isolation and
dereplication facilitates the prioritization of the isolates which
could be cellular factories with the innate biosynthetic capability
to produce novel compounds. One such approach has been
practiced to isolate 64 distinctive actinomycetes from 12 different
marine sponge species, and to prioritize two unique strains
that showed anti-trypanosomal activity as well as uniqueness
in metabolomic profile and richness of unidentified natural
products (Cheng et al., 2015).
Prediction and identification of novel compounds from
actinomycetes including those with low production titers have
become relatively straight forward through the advent of high-
resolution liquid chromatography-mass spectrometry (HR-LC-
MS) and allied database search (Tawfike et al., 2013; Doroghazi
et al., 2014; Wu et al., 2016). Recently, Wu et al. (2016) were
able to demonstrate the employability of NMR-based metabolic
profiling method to streamline microbial biotransformation and
to determine the best harvesting time of actinomycetes for
antibiotic production. Technical breakthroughs also in gene
level understanding and recombineering of producer strains
provide an attractive choice to improve the production titers of
structurally complex natural products by microbial fermentation
(Zhang et al., 2016).
Exploring the biology of secondary metabolites production
in actinomycetes through genetics has provided a foremost
share to our current knowledge. Dramatic and sustained
increase in understanding the genetics and enzymology of
secondary metabolites biosynthesis in actinomycetes, especially
Streptomyces throughout the 1990s have also facilitated
endurance of natural product search in this admirable bacterial
group. As a noteworthy foundation, S. coelicolor A3(2) has
genetically been recognized as a model for the actinomycetes,
and the whole genome was announced with versatile in vivo
and in vitro genetics (Bentley et al., 2002). The genome analysis
of S. coelicolor A3(2) has revealed the abundance of previously
uncharacterized gene clusters, metabolic enzymes, particularly
those likely to be involved in the production of natural products.
As a latest accomplishment, the marine actinomycete genus
Salinispora has been established as a robust model organism for
natural product research (Jensen et al., 2015). It has remarkable
biosynthetic capacities with 17 diverse biosynthetic pathways of
which only four had been linked to their respective products.
The genome information of cultured and uncultured
actinomycetes is being promptly updated. Over 1304
actinomycetes genome have been reported as on March 2016
and with the advent of molecular genetics and next-generation
genome analysis rapid submissions are expected in near future.
Analyses of genomes of actinomycetes have revealed that
numerous ‘cryptic’ or ‘orphan’ biosynthetic gene clusters with the
potential to direct the production of an ample number of novel,
structurally diverse natural products (Challis, 2014; Gomez-
Escribano et al., 2016). Subsequently, mining of actinomycetes
genome has sketched new directions into the ongoing drug
discovery efforts. One such approach has been to mine a
collection of 10,000 actinomycetes for novel phosphonic acids,
and have laid an intriguing foundation for rapid, large-scale
discovery of other classes of natural products (Ju et al., 2015).
Improvements made in bioinformatics methods, particularly
specific for natural product gene cluster identification and
functional prediction aids in the processing of bulk genomic
data of actinomycetes (Alam et al., 2011; Doroghazi et al., 2014;
Abdelmohsen et al., 2015). However, sufficient insights into
the biology and ecology of antibiotic production are needed to
understand the precise triggers and cues required to activate
silent gene clusters (Abdelmohsen et al., 2015; Kolter and
van Wezel, 2016).
As a great breakthrough, the advent of RNA-guided
DNA editing technology Clustered Regularly Interspaced Short
Palindromic Repeats (CRISPRs)/Cas9 substantially promises for
application to genome modification in biosynthetic gene clusters
of actinomycetes (Huang et al., 2015). Obviously, this molecular
tool can be used in the engineering of non-model native
hosts to heterologous production hosts for the biosynthesis
of desired natural products. Continued technological and
conceptual advances in engineering microbial hosts will open up
opportunities to fully explore and harness Nature’s immensely
diverse chemical repertoire (Zhang et al., 2016).
FUTURE PERSPECTIVES
Actinomycetes have been recognized as a premier source
of biopharmaceuticals especially antibiotics over several
decades. Our universe is rich of diverse unexplored and
underexplored environments that could be considered for
isolation of novel members of actinomycetes. This could
amend our actinomycetes repository with a continuous supply
of novel biosynthetic gene clusters and natural product
scaffolds on which current research reorient on. Continued
advances in genomics and metabolomics reserve a next-
generation natural products research and unwrap the wider
opportunities on the exploitation of actinomycetes that represent
an important asset for the discovery of pharmaceutically
valuable compounds. The technological and conceptual
advances will drive a transition of “searching for desired
natural products” to “designing for desired products” from
actinomycetes. Through this article, it is evinced that despite
an interim decline in actinomycetes research, new avenues
are open now and seek the active attention of researchers
throughout the world. Those countries well endowed with
the natural resources may deem to fund microbial natural
products research especially actinomycetes research for
extending the inventions of novel antibiotics of industrial
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significance to triumph the escalating microbial resistance and
infectious diseases.
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